| 翻訳と辞書 |
| Alkermes (company) ： ウィキペディア英語版 |
Alkermes (company)
Alkermes plc is a biopharmaceutical company that focuses on central nervous system (CNS) diseases. The company is the result of a merger in September 2011 between Alkermes, Inc. and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio.〔
== Products==
Alkermes has more than 20 commercial drug products and candidates that address serious and chronic diseases such as addiction, schizophrenia, diabetes and depression. Among these, five products are primary to the company: risperidone long-acting Injection (generic for ''Risperdal Consta'') for schizophrenia and bipolar 1 disorder,〔Zacks Equity Research, “(Positive Data on Risperdal Consta ),” Yahoo! Finance, March 29, 2011.〕〔John M. Grohol, “(Risperdal Consta Approved for Bipolar ),” PsychCentral.com, May 18, 2009.〕 paliperidone palmitate (generic for ''Invega Sustenna'' in the U.S., ''Xeplion'' in Europe) for schizophrenia,〔Cole Petrochko, “(FDA Okays First Monthly Antipsychotic Drug ),” MedPage Today, August 5, 2009.〕〔Matt Jarzemsky, “(Johnson & Johnson Gets European Approval For Schizophrenia Shot ),” ''The Wall Street Journal'', March 9, 2011.〕 4-aminopyridine (generic for ''Ampyra'' in the U.S., ''Fampyra'' in Europe) to improve walking in patients with multiple sclerosis,〔Susan Jeffrey, “(FDA Approves Dalfampridine to Improve Walking in Multiple Sclerosis ),” Medscape Medical News, January 22, 2010.〕〔Toni Clarke, “(Europe backs Acorda, Biogen drug in change of tack ),” Reuters, May 20, 2011.〕 naltrexone for extended-release injectable suspension (generic for ''Vivitrol'') for alcohol and opioid dependence,〔Miranda Hitti, “(FDA OKs New Drug to Treat Alcoholism ),” WebMD, April 14, 2006.〕〔Rita Rubin, “(FDA OKs Vivitrol to treat heroin, narcotic addictions ),” ''USA Today'', October 13, 2010.〕 and exenatide extended-release for injectable suspension (generic for ''Bydureon'') for the treatment of type 2 diabetes. ''Bydureon'' is a once-weekly, extended-release form of the drug, exenatide (''Byetta''), and was developed through a partnership between Amylin Pharmaceuticals, Alkermes and Eli Lilly. It is approved in Europe and the U.S.〔Denise Mann, "(Weekly Shot Gets FDA Nod for Type 2 Diabetes )," WebMD, January 27, 2012〕
ALKS-5461, a κ-opioid receptor antagonist, is a next-generation, novel antidepressant which is under development by Alkermes for treatment-resistant depression.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Alkermes (company)」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|